


State of California—Health and Human Services Agency California Department of Public Health



November 23, 2011

IZB-FY-1112-05

TO: Vaccines for Children (VFC) Providers

FROM: John Talarico, D.O., M.P.H., Chief

Center for Infectious Diseases

Division of Communicable Disease Control, Immunization Branch

Subject: Expanded Indications for MCV4 include High-Risk Children

Summary

In addition to a routine dose at 11-12 years old and a booster dose for adolescents at age 16 years, ACIP now also recommends meningococcal conjugate vaccine (MCV4) for high-risk children as young as 9 months of age.

New: MCV4 for High-Risk Children as Young as Age 9 months

In October 2011, ACIP provided expanded recommendations for the use of quadrivalent meningococcal conjugate vaccine (MCV4) in children as young as 9 months of age who are at increased risk of developing meningococcal disease.

<u>Children 9 months-23 months of age</u> with the following risks should receive a primary series of **2 doses of MCV4, 3 months apart:**

- Those with persistent complement component deficiencies
- Traveling to or residing in countries where meningococcal disease is hyperendemic or epidemic
- In a defined risk group during a community or institutional meningococcal outbreak

<u>Children 2- 10 years of age</u> with the following risks should receive a primary series of **2 doses of MCV4, 2 months apart**:

- Functional or anatomic asplenia
- Persistent complement component deficiencies and no prior doses of MCV4
- At increased risk of meningococcal disease and infected with HIV

<u>Children 2-10 years of age not previously immunized with MCV4</u> and with the following risks **should receive 1 dose of MCV4**:

- Traveling to or reside in countries where meningococcal disease is hyperendemic or epidemic;
- In a defined risk group during a community or institutional meningococcal outbreak.

Reminder: ACIP recommends a booster dose of MCV4 for Older Adolescents

Age in years at first dose of MCV4	Age in years for booster dose
11 or 12	16
13 through 15	16 through 18
>16	No booster dose needed.

Current FDA License Age Indications for MCV4

- Menactra® (sanofi pasteur) -- 9 months through 55 years of age.
- Menveo® (Novartis Vaccines and Diagnostics, Inc.) -- 2 through 55 years of age.

Vaccine Information Statement (VIS)

The updated MCV4 vaccine information statement, with new information on contraindications, precautions and adverse events, can be downloaded at www.EZIZ.org.

ACIP Recommendations on MCV4

Providers are encouraged to review the details of ACIP recommendations for MCV4:

- Use in children as young as 9 months October 2011 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm
- Use in high-risk children age 2 through 10 years; updated booster guidance -August 2011 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6030a3.htm
- Adolescent booster dose January 2011 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm
- Revaccination of persons at prolonged increased risk for meningococcal disease
 September 2009
 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm?s cid=mm5837a4

Questions?

If you have any questions, please call your VFC Field Representative or the VFC Program at 877-243-8832 (877-2GET-VFC) or visit www.EZIZ.org.

Expanded Indications for MCV4 include High-Risk Children November 23, 2011 Page 3 of 3

cc: CDPH Immunization Branch Field Representatives

Local Health Officers

Local Health Department Immunization Coordinators

Local Health Department CHDP Program Directors

Jane Ogle, Acting Chief, Medi-Cal Managed Care Division, DHCS

Shabbir Ahmad, D.V.M., M.S., Ph.D., Acting Chief, Maternal, Child and Adolescent Health Program, CDPH

Laurie Weaver, Chief, Office of Family Planning, CDPH

Shelley Rouillard, Deputy Director, Benefits and Quality Monitoring Division, MRMIB

Emmee Nguyen, Benefits and Quality Monitoring, MRMIB

Jill Young, Benefits and Quality Monitoring, MRMIB

Sherie Smalley, M.D., Chief, Medi-Cal Policy and Benefits Branch, Medi-Cal Benefits, Waiver Analysis and Rates Division, DHCS

Steve Shih, M.D. Medical Policy Section, Medi-Cal Benefits, Waiver Analysis and Rates Division, DHCS

Alan Morita, Pharm.D., Medi-Cal Pharmacy Policy Branch, DHCS

Robert Dimand, M.D., Chief, Children Medical Services Branch, DHCS

Jill Abramson, M.D., M.P.H., Children Medical Services Branch, DHCS